Wil Ward (@Wil_Ward_) header
Wil Ward (@Wil_Ward_) profile picture
Chicago, IL
Joined September 2022
Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)Photo by Wil Ward (@Wil_Ward_)
Wil Ward retweeted
A brief reply to @Wil_Ward_ 's recent @Sensible__Med article on the cardiac defibrillator by @drjohnm open.substack.com/pub/sensib…
3
12
2,933
Today in @Sensible__Med, @drjohnm responds to my article and adds important context about the Wearable Cardiac Defibrillator (WCD). His post is amazing. If you are a paid subscriber, please read. If not, I recommend you become one! Should the WCD still be used, even though it failed a clinical trial? I think John's argument for limited use despite VEST makes a lot of sense. It is an honor to write for @Sensible__Med. An even bigger honor to receive this response from @drjohnm, who I consider one of the most important thinkers and writers in medicine. He improves my thinking every week on Sensible Medicine. And this week, he did it twice 🙏
1
3
6
3,085
Great pickup
Good piece. The manuscript hides another strong argument against the "the vest works if worn" crowd: 9 of the 25 patients who had "arrhythmic deaths" were wearing the vest at the time.
5
25
10,949
I was excited to read this submission to @Sensible__Med from @Wil_Ward_ on anecdote not being data. Then I got even more excited because it used the wearable cardiac defibrillator and VEST trial as an example. Superb. Superb. Please do read sensible-med.com/p/i-see-it-…
6
13
3
47
14,110
Wow! Not one, 2 @JCO_ASCO articles in less than 2 months "defending" adjuvant CDK4/6 inhibitors in patients with early breast cancer! Parlty in response of our works @vkprasadlab Stakes are high, up to 40% of patients with newly diagnosed breast cancer could be eligible. 👉For an alternative perspective on the data, see The Oncology Shot ! (+ more on that topic soon, stay tuned)
6
6
1
36
4,353
Wil Ward retweeted
One of my best friends was a superb primary care physician. The stresses outlined in this excellent piece are why she elected to retire early. @adamcifu sensible-med.com/p/concierge…
6
30
2
89
29,217
Are GLP1s the next big thing in secondary stroke prevention? This RCT (LAMP) randomized participants with type 2 diabetes and recent stroke to either liraglutide or "control". The trial design and supplemental materials leave me unconvinced. jamanetwork.com/journals/jam…
1
1
5
908
LAMP results are implausible. The effect size is larger than I would expect (RRR 44%). How could a medicine meant to affect metabolic health over months and years exclusively produce benefit in the first 30 days!? We need a placebo-controlled trial before changing practice.
1
103
Critical letter in JAMA Psychiatry responding to Kalfas et al. The meta-analysis concluded no link between treatment duration and withdrawal severity, but relied almost entirely on 8-12 week trials. This overlooked the real issue: long-term use. Glad to see this published.
My letter with @ReadReadj and @PloederlM has now been published in JAMA Psychiatry. We comment on the meta-analysis by Kalfas et al, which concluded that withdrawal reactions from antidepressants are rare and transient and thus of no clinical relevance. jamanetwork.com/journals/jam…
1
3
1
17
2,243
fascinating trial from 18 public hospitals in Kenya! Steroids work safe to say its driven by severe CAP with hypoxia Rare example where the subgroup analysis is very helpful there is prior evidence of benefit if hypoxic & on oxygen vs not Not flukish
Presented at #LIVES2025: In a pragmatic trial conducted in general medical wards with limited diagnostic and therapeutic resources in Kenya, glucocorticoids reduced mortality in patients with community-acquired pneumonia. Full trial results: nej.md/47glh02 Editorial: Glucocorticoids for Pneumonia in Africa — Old Therapy, New Context nej.md/4qgjdxH
2
1
1
16
4,491
This is a good one. Don't miss it.
Thinking about the latest, best, though still inadequate, COVID vaccine study. Association of 2024-2025 COVID-19 Vaccine with COVID-19 Outcomes in U.S. Veterans sensible-med.com/p/associati…
3
560
It is disturbing that when explaining an intervention, it is typical for physicians with decades of experience to defend it with mechanistic or guideline-centered thinking. When pressed for evidence, few can provide it. @drjohnm is right. We must do better as a profession.
What @drjohnm sees is that doctors simply accept what guideline writers put into those colored boxes: Which would b fine if guidelines were written by neutral Martians free of dualities of interests. But that’s not the case open.substack.com/pub/johnma… @Coronary4front @gbiondizoccai
2
5
14
10,071
Check out our latest in @JAMAInternalMed: the rising incidence of early-onset cancer is largely an epidemic of diagnosis, not disease jamanetwork.com/journals/jam…
3
14
5
39
14,513
"You're a smart boy. But you have one great fault: you do not let yourself be told anything." - Heinrich Weber (physics professor) to a young Albert Einstein
5
135
This @Sensible__Med piece by @CoryRohlfsen is one of his best. Definitely worth reading. open.substack.com/pub/sensib…
1
3
10
1,266
This trial is odd. It is a non-inferiority RCT that compares SSRIs and writing exposure therapy (WET) for PTSD. Outcomes were based on an 80-point PTSD severity scale, PCL-5. There was no placebo or wait list group to compare how much symptoms would improve with no treahment. The authors conclude the "findings suggest that clinically meaningful improvements in PTSD symptom severity can be achieved in primary care with either SSRIs or WET, thus providing clinicians with evidence to recommend either treatment option to their patients" But this conclusion seems like a stretch for several reasons: 1) The trial is run based on the assumption that WET is effective. But the only cited trial meant to establish absolute efficacy included 46 (!) patients. 2) SSRIs only improve symptoms by perhaps 4 points on PCL-5 compared to placebo. In this trial, symptoms with WET improved 1.9 points less compared to SSRIs. While this difference was not statistically significant, we should be cautious about the possibility that WET may underperform an intervention of debatable clinical significance If anything, this demonstrates the clinical utility of WET should be re-examined in a larger RCT meant to establish absolute efficacy. The benefit may not achieve either clinical significance or statistical significance. Before retraining the entire workforce of therapists, maybe we should require stronger direct evidence.
2
3
35
4,428